Attention-Deficit/Hyperactivity Disorder in Adults: Evidence-Based Recommendations for Management

References

• Wilens TE, Biederman J, Spencer TJ. Attention deficit hyperactivity disorder across the lifespan. Annu Rev Med. 2002; 53: 113–131.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler LA, Ames M, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med. 2005; 47(6): 565–572.
   PubMed Web of Science ®Google Scholar
• Murphy K, Barkley R. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disord. 1996; 1: 147–161.
   Google Scholar
• Heiligenstein E, Conyers LM, Berns AR, Miller MA. Preliminary normative data on DSM-IV attention deficit hyperactivity disorder in college students. J Am Coll Health. 1998; 46(4): 185–188.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003; 2(2): 104–113.
   PubMedGoogle Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006; 163(4): 716–723.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006; 36(2): 159–165.
   PubMed Web of Science ®Google Scholar
• Davidson MA. ADHD in adults: a review of the literature. J Atten Disord. 2008; 11(6): 628–641.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J, Spencer T, et al. Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry. 2000; 48(1): 9–20.
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993; 150(12): 1792–1798.
   PubMed Web of Science ®Google Scholar
• Barkley RA, Murphy KR, Dupaul Gl, Bush T. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc. 2002; 8(5): 655–672.
   PubMed Web of Science ®Google Scholar
• de Graaf R, Kessler RC, Fayyad J, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: Results from the WHO World Mental Health Survey Initiative. Occup Environ Med. In press.
   Google Scholar
• Sankaranarayanan J, Puumala SE, Kratochvil CJ. Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003. Curr Med Res Opin. 2006; 22(8): 1475–1491.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Spencer TJ, Montano CB, Biederman J. Attention-deficit/hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care. Arch Intern Med. 2004; 164(11): 1221–1226.
   PubMedGoogle Scholar
• Van Brunt DL, Johnston JA, Ye W, Pohl GM, O'Hara NN. Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data. J Manag Care Pharm. 2006; 12(3): 230–238.
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Wilens T. Stimulant treatment of adult attention deficit hyperactivity disorder. Psychiatr Clin North Am. 2004; 27(2): 361–372.
   PubMedGoogle Scholar
• McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention-deficit/hyperactivity disorder: Findings from multiplex families. Am J Psychiatry. 2005; 162(9): 1621–1627.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J, Spencer T, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry. 2006; 163(10): 1720–1729.
   PubMed Web of Science ®Google Scholar
• McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry. 2004; 161(11): 1948–1956.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2006. http://www.who.int/classifications/apps/icd/icd1Oonline/. Accessed November 30, 2006.
   Google Scholar
• Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British association for psychopharmacology. J Psychopharmacol. 2007; 21(1): 10–11.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J, Doyle A, et al. Neuropsychological studies of late onset and subthreshold diagnoses of adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006; 60(10): 1081–1087.
   PubMedGoogle Scholar
• Barkley RA, Murphy KR, Fischer M. ADHD in Adults: What the Science Says. New York, NY: Guilford Press; 2006.
   Google Scholar
• Greenhill LL, Pliszka S, Dulcan MK; American Academy of Child and Adolescent Psychiatry (AACAP). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002; 41(suppl 2): 26S–49S.
   PubMed Web of Science ®Google Scholar
• Wender PH, Reimherr FW, Wood DR. Attention-deficit disorder (‘minimal brain dysfunction’) in adults. A replication study of diagnosis and drug treatment. Arch Gen Psychiatry. 1981; 38(4): 449–456.
   PubMed Web of Science ®Google Scholar
• Brown T. Brown Attention Deficit Disorder Scales: Manual. San Antonio, TX: Pearson Education, Inc; 1996.
   Google Scholar
• Conners CK, Erhardt D, Sparrow E, Conners MA. CAARS Adult ADHD Rating Scales. New York, NY: Multi Health Systems; 1998.
   Google Scholar
• Adler LA, Kessler RC, Spencer T. Adult ADHD Self-Report Scale-v 1.1 (ASRS-v1.1) symptom checklist. NYU Langone Medical Center website. Updated 2004. http://www.med.nyu.edu/psych/assets/adhdscreenl8.pdf. Accessed November 27, 2006.
   Google Scholar
• Spencer T, Adler L. Diagnostic approaches to adult attention-deficit/hyperactivity disorder. Prim Psychiatry. 2004; 11: 49–53.
   Google Scholar
• Carpentier PJ, de Jong CA, Dijkstra BA, Verbrugge CA, Krabbe PF. A controlled trial of methylphenidate in adults with attention deficit hyperactivity disorder and substance use disorders. Addiction. 2005; 100(12): 1868–1874.
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Spencer T, et al. An open-label trial of OROS® methylphenidate in adults with late-onset ADHD. CNS Spectr. 2006; 11(5): 390–396.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2004; 24(1): 24–29.
   PubMed Web of Science ®Google Scholar
• Clausen SB, Read SC, Tulloch SJ. Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. CNS Spectr. 2005; 10(12 suppl 20): 6–15.
   PubMed Web of Science ®Google Scholar
• Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J Clin Pharmacol. 2000; 40(4): 379–388.
   PubMed Web of Science ®Google Scholar
• Wood DR, Reimherr FW, Wender PH, Johnson EG. Diagnosis and treatment of minimal brain dysfunction in adults. Arch Gen Psychiatry. 1976; 33(12): 1453–1460.
   PubMed Web of Science ®Google Scholar
• Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry. 1984; 41(11): 1059–1063.
   PubMedGoogle Scholar
• Wender PH, Reimherr FW, Wood D, Ward M. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry. 1985; 142(5): 547–552.
   PubMed Web of Science ®Google Scholar
• Gualtieri CT, Ondrusek MG, Finley C. Attention deficit disorder in adults. Clin Neuropharmacol. 1985; 8(4): 343–356.
   PubMed Web of Science ®Google Scholar
• Shekim WO, Asarnow RF, Hess E, Zaucha K, Wheeler N. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry. 1990; 31(5): 416–425.
   PubMed Web of Science ®Google Scholar
• Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995; 52(6): 434–443.
   PubMed Web of Science ®Google Scholar
• Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry. 1998; 59(6): 300–305.
   PubMedGoogle Scholar
• Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry. 2001; 13(3): 129–134.
   PubMedGoogle Scholar
• Bouffard R, Hechtman L, Minde K, Iaboni-Kassab F. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatry. 2003; 48(8): 546–554.
   PubMedGoogle Scholar
• Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, Kalma LE, Buitelaar JK. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperacti vity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med. 2004; 34(6): 973–982.
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005; 57(5): 456–463.
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyper-activity disorder. Biol Psychiatry. 2006; 59(9): 829–835.
   PubMed Web of Science ®Google Scholar
• Reimherr FW, Williams ED, Strong RE, et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry. 2007; 68(1): 93–101.
   PubMed Web of Science ®Google Scholar
• Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007; 68(2): 268–277.
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Adler LA, McGough JJ, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007; 61(12): 1380–1387.
   PubMed Web of Science ®Google Scholar
• Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008; 63(10): 981–989.
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick EO, Surman C, et al. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 2007; 7: 49.
   PubMed Web of Science ®Google Scholar
• Paterson R, Douglas C, Hallmayer J, Hagan M, Krupenia Z. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry. 1999; 33(4): 494–502.
   PubMed Web of Science ®Google Scholar
• Horrigan JP, Barnhill LJ. Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2000; 61(6): 414–417.
   PubMed Web of Science ®Google Scholar
• Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol. 2000; 10(4): 311–320.
   PubMed Web of Science ®Google Scholar
• Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001; 21(2): 223–228.
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001; 58(8): 775–782.
   PubMed Web of Science ®Google Scholar
• Biederman J, Spencer TJ, Wilens TE, Weisler RH, Read SC, Tulloch SJ. SLI381.304 study group. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005; 10(12 suppl 20): 16–25.
   PubMed Web of Science ®Google Scholar
• Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006; 11(8): 625–639.
   PubMed Web of Science ®Google Scholar
• Weiss M, Hechtman L. The Adult ADHD Research Group. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry. 2006; 67(4): 611–619.
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention deficit hyperactivity disorder across the lifecycle: a literature review. J Am Acad Child Adolesc Psychiatry. 1996; 35: 409–432.
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Wilens T. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004; 27(2): 373–383.
   PubMedGoogle Scholar
• Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1998; 155(5): 693–695.
   PubMed Web of Science ®Google Scholar
• Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003; 53(2): 112–120.
   PubMed Web of Science ®Google Scholar
• Adler LA, Spencer TJ, Milton DR, et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry. 2005; 66(3): 294–299.
   PubMed Web of Science ®Google Scholar
• Adler L, Dietrich A, Reimherr FW, et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry. 2006; 18(2): 107–113.
   PubMedGoogle Scholar
• Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord. 2008 Apr 30. [Epub ahead of print]
   Google Scholar
• Faraone SV, Biederman J, Spencer T, et al. Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis. Behav Brain Fund. 2005; 1: 16.
   PubMedGoogle Scholar
• Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatiy. 2002; 159(11): 1896–1901.
   PubMed Web of Science ®Google Scholar
• Jain U, Hechtman L, Quinn D, et al. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA): Canadian ADHD Practice Guidelines: 2006. http://www.caddra.ca/joomla/pdfs/caddraGuidelinesChapter06.pdf. Accessed June 22, 2006.
   Google Scholar
• Rostain AL, Ramsay JR. A combined treatment approach for adults with ADHD: results of an open study of 43 patients. J Atten Disord. 2006; 10(2): 150–159.
   PubMedGoogle Scholar
• Weiss M, Saften SA, Solanto MV, et al. Research forum on psychological treatment of adults with ADHD. J Atten Disord. 2008; 11(6): 642–651.
   PubMedGoogle Scholar
• Ramsay JR. Current status of cognitive-behavioral therapy as a psychosocial treatment for adult attention-deficit/hyperaetivity disorder. Curr Psychiatry Rep. 2007; 9(5): 427–133.
   PubMedGoogle Scholar
• Wilens TE, McDermott SP, Biederman J, Abrantes A, Hahesy A. Spencer TJ. Cognitive therapy in the treatment-of adults with ADHD: a systematic chart review of 26 cases. J Cognit Psychother. 1999; 13: 215–226.
   Google Scholar
• Hesslinger B, van Eist LT, Nyberg E, et al. Psychotherapy of attention deficit hyperactivity disorder in adults: a pilot study using a structured skills training program. Eur Arch Psychiatry Clin Neurosci. 2002; 252(4): 177–184.
   PubMed Web of Science ®Google Scholar
• Saften SA, Otto MW, Sprich S, Winett CL, Wilens TE, Biederman J. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther. 2005; 43(7): 831–842.
   PubMedGoogle Scholar
• Biederman J, Spencer TJ. Psychopharmacology of adults with attention-deficit/hyperactivity disorder. Prim Psychiatry. 2004; 11(7); 57–62.
   Google Scholar
• Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord. 2002; 5(4): 189–202.
   PubMedGoogle Scholar
• Olfson M, Marcus SC, Zhang HF, Wan GJ. Stimulant use in adults with attention-deficit/hyperactivity disorder. Poster presented at: the Annual Meeting of the American Psychiatric Association; May 20–25, 2006; Toronto, Canada.
   Google Scholar
• Swanson JM, Lerner MA, Gupta S, Shoulson I, Wigal S. Development of a new once-a-day formulation of methylphenidate for the treatment of ADHD. Arch Gen Psychiatry. 2003; 60(2): 204–211.
   PubMed Web of Science ®Google Scholar
• Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord. 2005; 9(1): 275–289.
   PubMedGoogle Scholar
• Vetter VL, Elia J, Erickson C, et al. American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008; 117(18): 2407–2423.
   PubMedGoogle Scholar
• Gutgesell H, Atkins D, Barst R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: A statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 1999; 99(7): 979–982.
   PubMedGoogle Scholar